ENOSI LIFE SCIENCES
Enosi Life Sciences is a drug research and development company providing therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldman in San Diego, California in 2020.
ENOSI LIFE SCIENCES
Industry:
Biotechnology Fitness Health Care Therapeutics Wellness
Founded:
2020-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.enosi-life.com
Total Employee:
1+
Status:
Active
Contact:
858-350-4392
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Berkeleylife
Berkeley Life is a wellness company focusing on cardiovascular health incorporating an app for monitoring Nitric Oxide and Blood Pressure.
BioMech Golf
BioMech Golf bases its research and development on the biological and physical sciences.
Parvus Therapeutics
Parvus Therapeutics is a novel class of therapeutics to reverse autoimmune disease without impairing normal immunity.
PatchAid
PatchAid is the result of research to develop a high-tech, matrix-style transdermal vitamin patch.
Rapid Reboot
Rapid Reboot provides a range of medical compression and electronic products as well as providing apparel and related accessories.
Current Employees Featured
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-09 | Enosi Life Sciences Appoints Dr. Patrick William Gray as Chief Executive Officer |
Official Site Inspections
http://www.enosi-life.com
- Host name: 103.20.194.182
- IP address: 103.20.194.182
- Location: Hong Kong
- Latitude: 22.25
- Longitude: 114.1667
- Timezone: Asia/Hong_Kong
More informations about "Enosi Life Sciences"
Enosi Life Sciences - Crunchbase Company Profile
Enosi Life Sciences is a drug research and development company providing therapeutics for autoimmune diseases and cancer.See details»
Enosi Life Sciences Corp. - Drug pipelines, Patents, Clinical trials ...
May 7, 2025 Enosi Life Sciences Corp., based in San Diego, California, is a private pharmaceutical firm established in 2018 by H. Michael Shepard and Marc Feldmann. The โฆSee details»
Enosi Life Sciences - Overview, News & Similar companies
Nov 29, 2021 Who is Enosi Life Sciences Enosi Life Sciences Corp. is a drug research and development company focused on providing industry-leading therapeutics for autoimmune โฆSee details»
Enosi Life Sciences - Org Chart, Teams, Culture & Jobs | The Org
View Enosi Life Sciences' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
ENOSI LIFE SCIENCES CORP. - OpenCorporates
Free and open company data on British Columbia (Canada) company ENOSI LIFE SCIENCES CORP. (company number BC1176245)See details»
Enosi Life Sciences
About: Enosi Therapeutics is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was โฆSee details»
Enosi Therapeutics Corporation
We would like to show you a description here but the site wonโt allow us.See details»
Enosi Life Sciences | VentureRadar
Enosi Life Sciences is creating second generation, improved anti-TNF therapeutics, more precisely targeted for more effective treatment of inflammation, autoimmune diseases and โฆSee details»
Michael Shepard - President and CEO at Enosi Life Sciences (Enosi โฆ
President and CEO at Enosi Life Sciences (Enosi-Life.com) · A recipient of the Harvard Medical School Warren Alpert Award and the Lasker Prize for Clinical Medicine, Shepard began his โฆSee details»
EIN 84-4345067 - Enosi Life Sciences Corp., San Diego, California
Enosi Life Sciences Corp. is a corporation in San Diego, California. The employer identification number (EIN) for Enosi Life Sciences Corp. is 844345067. EIN for organizations is sometimes โฆSee details»
Enosi Life Sciences - VentureRadar
"Enosi Life Sciences is creating second generation, improved anti-TNF therapeutics, more precisely targeted for more effective treatment of inflammation, autoimmune diseases and โฆSee details»
Enosi Life Sciences Appoints Dr. Patrick William Gray as Chief ...
Nov 9, 2021 About Enosi Life Sciences Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and โฆSee details»
Enosi Life Sciences - Profiles & Contacts - Crunchbase
Enosi Life Sciences is a drug research and development company providing therapeutics for autoimmune diseases and cancer.See details»
Enosi Life Sciences Corp. (Enosi Life Sciences Corp.) - ่ฏ็ฉ็ฎก็บฟ_ไธ โฆ
May 7, 2025 About Enosi Life Sciences Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and โฆSee details»
Patrick William Gray - CEO at Enosi Life Sciences | The Org
Before being named Enosi Life Sciences CEO, Dr. Gray served as CEO for Pascal Biosciences (2015-2021) and was CEO of Nura, Inc. (2003-2006). Dr. Gray has had close relationships โฆSee details»
Enosi Life Sciences Featured on Americaโs Next Investment
May 25, 2021 About Enosi Life Sciences Corp. Enosi Life Sciences Corp. is a drug research and development company focused on providing industry-leading therapeutics for autoimmune โฆSee details»
EN-2642 - Drug Targets, Indications, Patents - Synapse
May 23, 2025 EN-2642: a EGF inhibitors, HER3 antagonists Drug, Initially developed by Enosi Life Sciences Corp., Now, its global highest R&D status is Preclinical, Mechanism: EGF โฆSee details»
A single approach to creating effective cancer and autoimmune โฆ
Jan 8, 2021 Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could โฆSee details»
EN-3001 - Drug Targets, Indications, Patents - Synapse
May 8, 2025 EN-3001: a TNFR2 antagonists Drug, Initially developed by Enosi Life Sciences Corp., Now, its global highest R&D status is Preclinical, Mechanism: TNFR2 antagonists โฆSee details»
EN-1206-Fc - Drug Targets, Indications, Patents - Synapse
May 23, 2025 EN-1206-Fc: a TNFR1 inhibitors Drug, Initially developed by Enosi Life Sciences Corp., Now, its global highest R&D status is Preclinical, Mechanism: TNFR1 inhibitors (Tumor โฆSee details»